Fusion Pharmaceuticals Inc.

When AstraZeneca bought Canadian radiopharmaceuticals firm Fusion Pharmaceuticals in March 2024 for $2bn, it came hot on the heels of other big pharma trying to get a piece of radio conjugate action t

The surge of interest in radiopharmaceuticals for both diagnostics and therapeutics is likely to prove very beneficial for Germany’s PentixaPharm GmbH which has a promising treatment for CNS lymphom

After a strong start to biopharma merger-and-acquisition activity in the first quarter of 2024, transactions declined notably in the second quarter, according to data provided by Evaluate. The second

It has felt lately that there may be not be enough radiopharmaceutical companies to satisfy big pharma’s appetite. First, in December 2023, Eli Lilly and Company purchased POINT Biopharma Global In